Meghan Morris, PhD

Headshot of Meghan Morris
User Profile Photo

Meghan Morris, PhD

User Profile Name
Associate Professor, School of Medicine
CTSI Profile Title
User Profile Email
Visit CTSI Profile

Biography

I am a mixed-method epidemiologist with graduate training in infectious disease and social epidemiology. I am interested understanding the biological, contextual, and policy aspects that place injection drug users at greater risk for HIV, hepatitis C infection and other negative health outcomes.

User Profile Bio

Displaying 26 - 50 of 58

  1. Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Lauer G, Cox AL, Hellard M, Dietze P, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, Page K, InC3 Collaborative . The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clin Infect Dis. 2018 01 06; 66(1):20-28.
    http://www.ncbi.nlm.nih.gov/pubmed/29020200
  2. Morris MD, Montgomery ME, Briceno A, Evans JL, Andrew EVW, Page K, Hahn JA. A Study of Sexual Relationship Power among Young Women Who Inject Drugs and Their Sexual Partners. Subst Use Misuse. 2018 07 03; 53(8):1281-1287.
    http://www.ncbi.nlm.nih.gov/pubmed/29286888
  3. Tiberio J, Laurent YI, Ndayongeje J, Msami A, Welty S, Ngonyani A, Mwankemwa S, Makumbuli M, McFarland W, Morris MD. Context and characteristics of illicit drug use in coastal and interior Tanzania. Int J Drug Policy. 2018 01; 51:20-26.
    http://www.ncbi.nlm.nih.gov/pubmed/29156310
  4. Morris MD, Brown B, Allen SA. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health. Int J Prison Health. 2017 09 11; 13(3-4):192-199.
    http://www.ncbi.nlm.nih.gov/pubmed/28914118
  5. Morris MD, Neilands TB, Andrew E, Maher L, Page KA, Hahn JA. Development and validation of a novel scale for measuring interpersonal factors underlying injection drug using behaviours among injecting partnerships. Int J Drug Policy. 2017 10; 48:54-62.
    http://www.ncbi.nlm.nih.gov/pubmed/28804051
  6. Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, Cox AL, Dore G, Grebely J, Kim AY, Lauer GM, Lloyd A, Rice T, Shoukry N, Maher L, Page K, International Collaboration of Incident HIV and HCV in
    Injecting Cohorts (InC3) . Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clin Infect Dis. 2017 Apr 01; 64(7):860-869.
    http://www.ncbi.nlm.nih.gov/pubmed/28362947
  7. Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA, InC(3) Study Group . Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infect Genet Evol. 2017 04; 49:88-96.
    http://www.ncbi.nlm.nih.gov/pubmed/28065804
  8. Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F, International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study Group . Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis. 2016 Nov 01; 214(9):1383-1389.
    http://www.ncbi.nlm.nih.gov/pubmed/27571901
  9. Baer RJ, Rogers EE, Partridge JC, Anderson JG, Morris M, Kuppermann M, Franck LS, Rand L, Jelliffe-Pawlowski LL. Population-based risks of mortality and preterm morbidity by gestational age and birth weight. J Perinatol. 2016 11; 36(11):1008-1013.
    http://www.ncbi.nlm.nih.gov/pubmed/27467566
  10. Page K, Mirzazadeh A, Rice TM, Grebely J, Kim AY, Cox AL, Morris MD, Hellard M, Bruneau J, Shoukry NH, Dore GJ, Maher L, Lloyd AR, Lauer G, Prins M, McGovern BH. Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infect Dis. 2016 Jan; 3(1):ofw024.
    http://www.ncbi.nlm.nih.gov/pubmed/26973850
  11. Morris MD, Bates A, Andrew E, Hahn J, Page K, Maher L. More than just someone to inject drugs with: Injecting within primary injection partnerships. Drug Alcohol Depend. 2015 Nov 01; 156:275-281.
    http://www.ncbi.nlm.nih.gov/pubmed/26460140
  12. Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, Matthews G, Rice TM, Morris MD, McGovern BH, Kim AY, Bruneau J, Lloyd AR, Page K, Manns MP, Hellard ME, Dore GJ, InC3 Study Group . Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat. 2015 Dec; 22(12):1020-32.
    http://www.ncbi.nlm.nih.gov/pubmed/26098993
  13. Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Shoukry NH, Schinkel J, Allen TM, Morris M, Hajarizadeh B, Maher L, Lloyd AR, Page K, Hellard M, InC3 study group . Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. J Infect Dis. 2015 Nov 01; 212(9):1407-19.
    http://www.ncbi.nlm.nih.gov/pubmed/25883387
  14. Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ, Grebely J, InC3 Study Group . Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One. 2015; 10(4):e0122232.
    http://www.ncbi.nlm.nih.gov/pubmed/25837807
  15. Spelman T, Morris MD, Zang G, Rice T, Page K, Maher L, Lloyd A, Grebely J, Dore GJ, Kim AY, Shoukry NH, Hellard M, Bruneau J, International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3 Study) . A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. J Epidemiol Community Health. 2015 Aug; 69(8):745-52.
    http://www.ncbi.nlm.nih.gov/pubmed/25814695
  16. Morris MD, Evans J, Montgomery M, Yu M, Briceno A, Page K, Hahn JA. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. PLoS One. 2014; 9(10):e109282.
    http://www.ncbi.nlm.nih.gov/pubmed/25286346
  17. Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J, InC(3)Study Group . Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol. 2014 Nov; 61(3):430-4.
    http://www.ncbi.nlm.nih.gov/pubmed/25256151
  18. Evans JL, Morris MD, Yu M, Page K, Hahn JA. Concordance of risk behavior reporting within HCV serodiscordant injecting partnerships of young injection drug users in San Francisco, CA. Drug Alcohol Depend. 2014 Sep 01; 142:239-44.
    http://www.ncbi.nlm.nih.gov/pubmed/25034898
  19. Tracy D, Hahn JA, Fuller Lewis C, Evans J, Briceño A, Morris MD, Lum PJ, Page K. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open. 2014 May 29; 4(5):e004988.
    http://www.ncbi.nlm.nih.gov/pubmed/24875490
  20. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M, InC3 Study Group . The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014 Jan; 59(1):109-20.
    http://www.ncbi.nlm.nih.gov/pubmed/23908124
  21. Briceño A, Morris MD, Evans J, Raymond HF, Page K. Characteristics and health service utilization in two samples of young injection drug users recruited using direct and referral methods in San Francisco, California. J Alcohol Drug Depend. 2013 Aug; 1(5).
    http://www.ncbi.nlm.nih.gov/pubmed/26236757
  22. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013 Aug; 57 Suppl 2:S32-8.
    http://www.ncbi.nlm.nih.gov/pubmed/23884063
  23. Morris MD, Quezada L, Bhat P, Moser K, Smith J, Perez H, Laniado-Laborin R, Estrada-Guzman J, Rodwell TC. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient's perspective. Int J Tuberc Lung Dis. 2013 Jul; 17(7):954-60.
    http://www.ncbi.nlm.nih.gov/pubmed/23743315
  24. B. Hajarizadeh, K. Page, A.Y. Kim, B.H. McGovern, A.L. Cox, T.M. Rice, R. Sacks-Davis, J. Bruneau, M. Morris, J. Amin, B. Grady, J. Schinkel, L. Maher, M. Hellard, A.R. Lloyd, M. Prins, J. Grebely, G.J. Dore, on behalf of the InC Study Group. 1157 EARLY HCVRNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCVRNA LEVEL DURING ACUTE HCV INFECTION. Journal of Hepatology. 2013 Apr 1; 58:s470-s471.
  25. Briceno A, Morris M.D., Evans J,Fisher R.H., and Page K,. Characteristics and Health Service Utilization in Two Samples of Young Injection Drug Users Recruited Using Direct and Referral Methods in San Francisco, California. Alcoholism & Drug Dependence. 2013; 1(5).